SCYNEXIS Receives Merial Research Collaboration Milestone Payment
Want to listen to this article for FREE?
Complete the form below to unlock access to ALL audio articles.
Read time: Less than a minute
Merial Limited and SCYNEXIS, Inc. have announced that SCYNEXIS has earned a fourth payment for meeting certain milestones in a multi-year research collaboration which began in 2005.
SCYNEXIS, a premier drug discovery and development company, directs considerable medicinal chemistry, advanced biological screening, bioanalytical and ADMET activities towards Merial's animal health discovery efforts.
"SCYNEXIS is pleased to earn another important research milestone through our valued partnership with Merial," said SCYNEXIS President and Chief Executive Officer Dr. Yves Ribeill. "This is the fourth consecutive milestone we have reached for delivering significant, innovative animal health development candidates to Merial under the agreement."
"Merial is delighted to see this latest success resulting from our pharmaceutical discovery collaboration with SCYNEXIS. This exciting addition to Merial's pharmaceutical pipeline shows what can be achieved when the best outside skills and resources are combined with Merial's in-house knowledge and expertise," said Dr. Christian Miculka, Head Discovery & Research.
SCYNEXIS, a premier drug discovery and development company, directs considerable medicinal chemistry, advanced biological screening, bioanalytical and ADMET activities towards Merial's animal health discovery efforts.
"SCYNEXIS is pleased to earn another important research milestone through our valued partnership with Merial," said SCYNEXIS President and Chief Executive Officer Dr. Yves Ribeill. "This is the fourth consecutive milestone we have reached for delivering significant, innovative animal health development candidates to Merial under the agreement."
"Merial is delighted to see this latest success resulting from our pharmaceutical discovery collaboration with SCYNEXIS. This exciting addition to Merial's pharmaceutical pipeline shows what can be achieved when the best outside skills and resources are combined with Merial's in-house knowledge and expertise," said Dr. Christian Miculka, Head Discovery & Research.
